SLC5A2 and diabetes mellitus: The SGLT2 inhibitor empagliflozin has been shown to reduce levels of inflammatory factors including IL-1, IL-6, and IL-8 in models of diabetics [13] and decrease mitochondrial calcium overload and reactive oxygen species production in human endothelial cells, which are caused by high glucose levels [14].